RUGEN HOLDINGS CAYMAN LTD has a total of 33 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are GOVEK STEVEN P, AXXONIS PHARMA AG and UAF TECHNOLOGIES AND RES LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | Australia | 3 | |
#5 | China | 3 | |
#6 | Brazil | 2 | |
#7 | Hong Kong | 1 | |
#8 | Israel | 1 | |
#9 | Republic of Korea | 1 | |
#10 | Mexico | 1 | |
#11 | Singapore | 1 | |
#12 | Taiwan | 1 | |
#13 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Shapiro Gideon | 29 |
#2 | Gideon Shapiro | 3 |
#3 | Flood Dorothy G | 3 |
#4 | Verdoorn Todd A | 2 |
#5 | Chen Gang | 2 |
#6 | Liu Jie | 2 |
Publication | Filing date | Title |
---|---|---|
EP3544610A1 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | |
KR20180032533A | A 3,3-difluoropiperidine carbamate heterocyclic compound as an NR2B NMDA receptor antagonist | |
WO2016126869A1 | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists | |
WO2016049048A1 | Treatment of anxiety disorders and autism spectrum disorders | |
WO2016044323A1 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists | |
AU2015271719A1 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |